Enlivex Therapeutics Secures $212M Private Investment for New RAIN Prediction Markets Token Treasury Strategy.

Enlivex Therapeutics (ENLV) has secured a $212 million private investment to launch a new RAIN prediction markets token treasury strategy. The funds will support the company's ongoing dedication to maintaining and enhancing its core business operations in the biotechnology sector. Enlivex's financial health presents a mixed picture, with strong liquidity and low leverage but negative ROE and ROA. Valuation metrics reflect the developmental stage, with a P/B ratio of 1.36 and an analyst target price of $7. Institutional ownership is stable, but volatility is high at 58.84.